AKT1 and neoplasm: Aberrant stimulation of the PI3K/AKT signaling cascade has been extensively reported as a driver of tumor progression, poor prognosis, and the emergence of therapeutic resistance (Wei et al., 2019; Song et al., 2020; Tufail et al., 2024).